Last update March 30, 2022
Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Main tradenames from several countries containing Dienogest in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 91 | % |
Molecular weight | 311 | daltons |
Protein Binding | 90 | % |
VD | 0.55 | l/Kg |
pKa | 13.78 | - |
Tmax | 1.5 | hours |
T½ | 10 - 14 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dienogest is a progestogen structurally related to nortestosterone. It is used in the treatment of endometriosis and, associated with an estrogen, as a contraceptive. Oral administration.
A latest update no published data on excretion into breast milk were found.
Its pharmacokinetic data (high percentage of protein binding and wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Progesterone and other related progestin drugs are excreted into breast milk in clinically non-significant amount (Croxatto 1987, Betrabet 1987, Nilsson 1977) and no problems have been observed in infants whose mothers were treated with this medication. (Roy 2020, Bahamondes 2013, Dutta 2013, Shaamash 2005, Bjarnadóttir 2001, Díaz 1997)
During lactation progestin-only contraceptives are preferable to those combined with estrogen and, in this case, those with a lower dose of estrogen. (CDC 2016, 2013 y 2010, WHO/OMS 2015, Altshuler 2015, Berens 2015, CLM 2012)
For the first 4-6 weeks postpartum, non-hormonal methods are the first choice, followed by IUDs and progestogen implants. (Berens 2015, Mwalwanda 2013, Rowe 2013, CLM 2012)
See below the information of these related products: